tace

2. BACKGROUND
• 1 of the most
common
malignancies in
Asia
• Prevalence and
incidence >>>
HEPATOCELLULAR
CARCINOMA (HCC)
< 20% of patients are
suitable for liver-resection
surgery and transplantation
Have very poor
prognosis
TRANSARTERIAL
CHEMOEMBOLIZATION
(TACE)
Gold-standard
palliative
treatment of
unresectable
HCC.

3. Case Report
A 81 y.o. man with unresectable HCC
TACE was performed with a combination of Lipiodol
and Doxorubicin, without any other treatment
CT-scan imaging and liver function tests were
performed before and after the TACE

4. Case Report
July, 2011
Nodul: 6,7 x
5,7 x 5 cm
ALT: 53,4
AST: 263,8
Total Bil.: 0,57
Alb: 3,95
March,
2016
Nodul: 4,3 x
4,5 x6,7 cm
June,
2016
Nodul: 4,6 x
4 x 5,6 cm
Nov,
2016
ALT: 32,7
AST: 86,5
Total bil.:
0,26
Alb: 3.74
Jan, 2017
Nodul: 4,6 x
4,59 x 4,4 cm
ALT: 10
AST: 39
Total bil.: 0,83
Alb: 3,96
1st TACE in
Okt 2011
2nd TACE in
April 2016
3rd TACE in
Nov, 2016
4th TACE in
Jan, 2017
AFP:
1636

5. Discussion
Age factor, size of
tumor and liver
function test,
surgery can not be
applied to this
patient.
TACE was needed
as a palliative
treatment
Tumor size
decrease 52 %,
and the liver
function was
improved
The patient survive
almost 6 years
whereas in several RCTs, the most
common survival rate post TACE
(alone) treatment was 1 year.

6. Conclusions
• The continued TACE with a proper follow up,
can improved the disease and survival rate for
unresectable HCC patient. In this patient, he
survive until alamost 6 years with good quality
of life.